The curious origins of angioimmunoblastic T-cell lymphoma

Current Opinion in Hematology

Volumn 23, Issue 4, 2016, Pages 434-443

  Cortés, José R ^a   Palomero, Teresa ^a  

^a Department of Medicine   (United States)

Author keywords

angioimmunoblastic T cell lymphoma; DNMT3A; follicular T helper cell; RHOA; TET2

Indexed keywords

CD28 ANTIGEN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 2; PROTEIN KINASE FYN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; TRANSCRIPTOME; TUMOR MARKER;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; CARCINOGENESIS; CELL MATURATION; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HELPER CELL; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SOMATIC CELL GENETICS; SOMATIC MUTATION; TET2 GENE; THYROID FOLLICLE CELL; ANIMAL; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; GENOMICS; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPHOMA, T-CELL; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; BIOMARKERS, TUMOR; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPHOMA, T-CELL; MUTATION; RECEPTORS, ANTIGEN, T-CELL; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER; TRANSCRIPTOME;

EID: 84967185922     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000261     Document Type: Review

References (118)

1. De Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 2010; 148: 673-689
2. Federico M, Rudiger T, Bellei M. et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 2013; 31: 240-246
3. Xu B, Liu P. No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: a population-based study of 1207 cases. PLoS One 2014; 9: e92585
4. Martinez-Delgado B, Cuadros M, Honrado E. et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 2005; 19: 2254-2263
5. Ballester B, Ramuz O, Gisselbrecht C. et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006; 25: 1560-1570
6. Martinez-Delgado B. Peripheral T-cell lymphoma gene expression profiles. Hematol Oncol 2006; 24: 113-119
7. De Leval L, Rickman DS, Thielen C. et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007; 109: 4952-4963
8. Piccaluga PP, Agostinelli C, Califano A. et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 2007; 67: 10703-10710
9. Piccaluga PP, Agostinelli C, Califano A. et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 2007; 117: 823-834
10. Cuadros M, Dave SS, Jaffe ES. et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 2007; 25: 3321-3329
11. Iqbal J, Weisenburger DD, Greiner TC. et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010; 115: 1026-1036
12. Iqbal J, Wright G, Wang C. et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014; 123: 2915-2923
13. Iqbal J, Wilcox R, Naushad H. et al. Genomic signatures in T-cell lymphoma: how can these improve precision in diagnosis and inform prognosis?. Blood Rev 2016; 30: 89-100
14. Piccaluga PP, Navari M, Etebari M, Pileri S. Molecular genetics of peripheral T-cell lymphomas. eLS [Internet] 2015
15. Gaulard P, De Leval L. The microenvironment in T-cell lymphomas: emerging themes. Semin Cancer Biol 2014; 24: 49-60
16. Piccaluga PP, Tabanelli V, Pileri SA. Molecular genetics of peripheral T-cell lymphomas. Int J Hematol 2014; 99: 219-226
17. Dupuis J, Boye K, Martin N. et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 2006; 30: 490-494
18. Grogg KL, Attygalle AD, Macon WR. et al. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol 2006; 19: 1101-1107
19. Schaerli P, Willimann K, Lang AB. et al. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000; 192: 1553-1562
20. Kim CH, Rott LS, Clark-Lewis I. et al. Subspecialization of CXCR5θ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5θ T cells. J Exp Med 2001; 193: 1373-1381
21. Breitfeld D, Ohl L, Kremmer E. et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000; 192: 1545-1552
22. Chtanova T, Tangye SG, Newton R. et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol 2004; 173: 68-78
23. Ueno H, Banchereau J, Vinuesa CG. Pathophysiology of T follicular helper cells in humans and mice. Nat Immunol 2015; 16: 142-152
24. Vinuesa CG, Cook MC, Angelucci C. et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005; 435: 452-458
25. Vinuesa CG, Linterman MA, Yu D, MacLennan IC. Follicular helper T cells. Annu Rev Immunol 2016; 34. [Epub ahead of print].
26. Goenka R, Barnett LG, Silver JS. et al. Cutting edge: dendritic cell-restricted antigen presentation initiates the follicular helper T cell program but cannot complete ultimate effector differentiation. J Immunol 2011; 187: 1091-1095
27. Stone EL, Pepper M, Katayama CD. et al. ICOS coreceptor signaling inactivates the transcription factor FOXO1 to promote Tfh cell differentiation. Immunity 2015; 42: 239-251
28. Weber JP, Fuhrmann F, Feist RK. et al. ICOS maintains the T follicular helper cell phenotype by down-regulating Kruppel-like factor 2. J Exp Med 2015; 212: 217-233
29. Leavenworth JW, Verbinnen B, Yin J. et al. A p85alpha-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells. Nat Immunol 2015; 16: 96-106
30. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity 2014; 41: 529-542
31. Liu X, Nurieva RI, Dong C. Transcriptional regulation of follicular T-helper (Tfh) cells. Immunol Rev 2013; 252: 139-145
32. Nurieva RI, Chung Y, Martinez GJ. et al. Bcl6 mediates the development of T follicular helper cells. Science 2009; 325: 1001-1005
33. Yu D, Batten M, Mackay CR, King C. Lineage specification and heterogeneity of T follicular helper cells. Curr Opin Immunol 2009; 21: 619-625
34. Johnston RJ, Poholek AC, DiToro D. et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 2009; 325: 1006-1010
35. Hatzi K, Nance JP, Kroenke M.A. et al. BCL6 orchestrates Tfh cell differentiation via multiple distinct mechanisms. J Exp Med 2015; 212: 539-553
36. Qi H, Chen X, Chu C. et al. Tfh cell differentiation and their function in promoting B-cell responses. Adv Exp Med Biol 2014; 841: 153-180
37. Choi YS, Kageyama R, Eto D. et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 2011; 34: 932-946
38. Liu X, Chen X, Zhong B. et al. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature 2014; 507: 513-518
39. Kroenke MA, Eto D, Locci M. et al. Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation. J Immunol 2012; 188: 3734-3744
40. Kwon H, Thierry-Mieg D, Thierry-Mieg J. et al. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 2009; 31: 941-952
41. Nurieva RI, Chung Y, Hwang D. et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 2008; 29: 138-149
42. Liao W, Lin JX, Wang L. et al. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol 2011; 12: 551-559
43. Choi YS, Yang JA, Yusuf I. et al. Bcl6 expressing follicular helper CD4 T cells are fate committed early and have the capacity to form memory. J Immunol 2013; 190: 4014-4026
44. Suto A, Kashiwakuma D, Kagami S. et al. Development and characterization of IL-21-producing CD4θ T cells. J Exp Med 2008; 205: 1369-1379
45. Ma CS, Suryani S, Avery DT. et al. Early commitment of naive human CD4(θ) T cells to the T follicular helper (T(FH)) cell lineage is induced by IL-12. Immunol Cell Biol 2009; 87: 590-600
46. Schmitt N, Bustamante J, Bourdery L. et al. IL-12 receptor beta1 deficiency alters in vivo T follicular helper cell response in humans. Blood 2013; 121: 3375-3385
47. Schmitt N, Morita R, Bourdery L. et al. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity 2009; 31: 158-169
48. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005; 21: 247-269
49. Boulter E, Estrach S, Garcia-Mata R, Feral CC. Off the beaten paths: alternative and crosstalk regulation of Rho GTPases. FASEB J 2012; 26: 469-479
50. del Pozo MA, Vicente-Manzanares M, Tejedor R. et al. Rho GTPases control migration and polarization of adhesion molecules and cytoskeletal ERM components in T lymphocytes. Eur J Immunol 1999; 29: 3609-3620
51. Heasman SJ, Carlin LM, Cox S. et al. Coordinated RhoA signaling at the leading edge and uropod is required for T cell transendothelial migration. J Cell Biol 2010; 190: 553-563
52. Heasman SJ, Ridley AJ. Multiple roles for RhoA during T cell transendothelial migration. Small GTPases 2010; 1: 174-179
53. Mou F, Praskova M, Xia F. et al. The Mst1 and Mst2 kinases control activation of rho family GTPases and thymic egress of mature thymocytes. J Exp Med 2012; 209: 741-759
54. Corre I, Gomez M, Vielkind S, Cantrell DA. Analysis of thymocyte development reveals that the GTPase RhoA is a positive regulator of T cell receptor responses in vivo. J Exp Med 2001; 194: 903-914
55. Henning SW, Galandrini R, Hall A, Cantrell DA. The GTPase Rho has a critical regulatory role in thymus development. EMBO J 1997; 16: 2397-2407
56. Galandrini R, Henning SW, Cantrell DA. Different functions of the GTPase Rho in prothymocytes and late pre-T cells. Immunity 1997; 7: 163-174
57. Cleverley S, Henning S, Cantrell D. Inhibition of Rho at different stages of thymocyte development gives different perspectives on Rho function. Curr Biol 1999; 9: 657-660
58. Cleverley SC, Costello PS, Henning SW, Cantrell DA. Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma. Oncogene 2000; 19: 13-20
59. Zhang S, Konstantinidis DG, Yang JQ. et al. Gene targeting RhoA reveals its essential role in coordinating mitochondrial function and thymocyte development. J Immunol 2014; 193: 5973-5982
60. Pernis AB. Rho GTPase-mediated pathways in mature CD4θ T cells. Autoimmun Rev 2009; 8: 199-203
61. Palomero T, Couronne L, Khiabanian H. et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014; 46: 166-170
62. Sakata-Yanagimoto M, Enami T, Yoshida K. et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46: 171-175
63. Yoo HY, Sung MK, Lee SH. et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46: 371-375
64. Wang C, McKeithan TW, Gong Q. et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood 2015; 126: 1741-1752
65. Manso R, Sanchez-Beato M, Monsalvo S. et al. The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature. Blood 2014; 123: 2893-2894
66. Ondrejka SL, Grzywacz B, Bodo J. et al. Angioimmunoblastic T-cell lymphomas with the RHOA p.Gly17Val mutation have classic clinical and pathologic features. Am J Surg Pathol 2016; 40: 335-341
67. Rohde M, Richter J, Schlesner M. et al. Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols. Genes Chromosomes Cancer 2014; 53: 911-916
68. Kakiuchi M, Nishizawa T, Ueda H. et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 2014; 46: 583-587
69. Wang K, Yuen ST, Xu J. et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014; 46: 573-582
70. Nagata Y, Kontani K, Enami T. et al. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood 2016; 127: 596-604
71. Quivoron C, Couronne L, Della Valle V. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011; 20: 25-38
72. Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 2012; 366: 95-96
73. Cairns RA, Iqbal J, Lemonnier F. et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012; 119: 1901-1903
74. Tahiliani M, Koh KP, Shen Y. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930-935
75. Ito S, D'Alessio AC, Taranova OV. et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466: 1129-1133
76. Cimmino L, Abdel-Wahab O, Levine RL, Aifantis I. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 2011; 9: 193-204
77. Pronier E, Delhommeau F. Role of TET2 mutations in myeloproliferative neoplasms. Curr Hematol Malig Rep 2012; 7: 57-64
78. Abdel-Wahab O, Mullally A, Hedvat C. et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144-147
79. Vose JM. Update on T-cell lymphoma. Ann Oncol 2008; 19 (Suppl 4): iv74-iv76
80. Lemonnier F, Couronne L, Parrens M. et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 2012; 120: 1466-1469
81. Moran-Crusio K, Reavie L, Shih A. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11-24
82. Li Z, Cai X, Cai CL. et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011; 118: 4509-4518
83. Ko M, Bandukwala HS, An J. et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 2011; 108: 14566-14571
84. Ko M, Rao A. TET2: epigenetic safeguard for HSC. Blood 2011; 118: 4501-4503
85. Koh KP, Yabuuchi A, Rao S. et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011; 8: 200-213
86. Kunimoto H, Fukuchi Y, Sakurai M. et al. Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. Sci Rep 2012; 2: 273
87. Shide K, Kameda T, Shimoda H. et al. TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia 2012; 26: 2216-2223
88. Muto H, Sakata-Yanagimoto M, Nagae G. et al. Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J 2014; 4: e264
89. Ley TJ, Ding L, Walter MJ. et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433
90. Shah MY, Licht JD. DNMT3A mutations in acute myeloid leukemia. Nat Genet 2011; 43: 289-290
91. Thiede C. Mutant DNMT3A: teaming up to transform. Blood 2012; 119: 5615-5617
92. Parker SJ, Metallo CM. Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther 2015; 152: 54-62
93. Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010; 16: 387-397
94. Lu C, Venneti S, Akalin A. et al. Induction of sarcomas by mutant IDH2. Genes Dev 2013; 27: 1986-1998
95. Ward PS, Lu C, Cross JR. et al. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 2013; 288: 3804-3815
96. Paschka P, Schlenk RF, Gaidzik VI. et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28: 3636-3643
97. Rohr J, Guo S, Huo J. et al. Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia 2015. [Epub ahead of print].
98. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004; 23: 7990-8000
99. Lee SH, Kim JS, Kim J. et al. A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients. Haematologica 2015; 100: e505-e507
100. Xie M, Lu C, Wang J. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472-1478
101. Jaiswal S, Fontanillas P, Flannick J. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488-2498
102. Genovese G, Kahler AK, Handsaker RE. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-2487
103. Hollister K, Kusam S, Wu H. et al. Insights into the role of Bcl6 in follicular Th cells using a new conditional mutant mouse model. J Immunol 2013; 191: 3705-3711
104. Huang C, Hatzi K, Melnick A. Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. Nat Immunol 2013; 14: 380-388
105. Cerchietti L, Melnick A. Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?. Expert Rev Hematol 2013; 6: 343-345
106. Dupont T, Yang SN, Patel J. et al. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget 2016; 7: 3520-3532
107. Platt AM, Gibson VB, Patakas A. et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol 2010; 185: 1558-1567
108. Ahearne MJ, Allchin RL, Fox CP, Wagner SD. Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. Br J Haematol 2014; 166: 326-335
109. Yang Q, Modi P, Newcomb T. et al. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res 2015; 21: 1537-1542
110. Chavele KM, Merry E, Ehrenstein MR. Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production. J Immunol 2015; 194: 2482-2485
111. Zhang M, Yu G, Chan B. et al. Interleukin-21 receptor blockade inhibits secondary humoral responses and halts the progression of preestablished disease in the (NZB-NZW)F1 systemic lupus erythematosus model. Arthritis Rheumatol 2015; 67: 2723-2731
112. van der Fits L, Out-Luiting JJ, Tensen CP. et al. Exploring the IL-21-STAT3 axis as therapeutic target for Sezary syndrome. J Invest Dermatol 2014; 134: 2639-2647
113. Hong D, Kurzrock R, Kim Y. et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med 2015; 7: 314ra185
114. Klimatcheva E, Pandina T, Reilly C. et al. CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol 2015; 16: 6
115. Bejar R, Lord A, Stevenson K. et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014; 124: 2705-2712
116. Cheminant M, Bruneau J, Kosmider O. et al. Efficacy of 5-Azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma. Br J Haematol 2015; 168: 913-916
117. DiNardo C, Stein EM, Altman JK. et al. AG-221, an oral, selective, firstin-class, potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phase 1 study of IDH2 mutation-positive advanced hematologic malignancies. Haematol Eur Hematol Assoc Annu Meet 2015; 569
118. Stein EM. IDH2 inhibition in AML: finally progress?. Best Pract Res Clin Haematol 2015; 28: 112-115.